Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Silo Pharma, Inc.
Tue, January 26, 2021, 8:18 AM·2 min read
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
https://finance.yahoo.com/news/silo-pharma-reaches-terms-university-131800548.html
Have a look at this recent newsletter. Ready for your next potential triple digit gainer?
Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research.
I recommend you take a moment and click here and discover how you can get this stock’s name & ticker symbol.
insert-text-here
If I told you that psychedelic stocks were among some of the best stocks to buy for the next decade, you’d probably look at me funny. I wouldn’t blame you. But, believe it or not, psychedelic stocks are some of the best stocks to buy for the next 10 years. Here is where you need to go now to get the name of this secret stock before everyone else.
This specific secret company is making incredible strides in this sector. It is focused on bringing targeted medicine to market, through novel delivery systems, psychedelic assisted psychotherapy, and Active Pharmaceutical Ingredient grade psilocybin manufacturing. To that effect, while it is still early in the medicinal psychedelic space, hefty valuations are being placed on the most serious contenders competing for a slice of the $100 billion pie.
This Secret Company with a market capitalization of less than $30 million CAD, provides investors with an opportunity which could prove highly lucrative as the industry develops and matures! Just make sure you own a piece of it before it is too late.
Click Here to review a thorough report detailing the above on this "Secret Company" and discover for yourself why you need to invest in it right away!
insert-text-here
Sincerely,
Editor In Chief, OTCtipReporter Team
After announcing a partnership with $AIKI, $SILO inks a partnership with the University of Maryland. . https://cnafinance.com/silo-stock-silo-pharma-to-climb-on-sponsored-research-agreement/
Silo Pharma : Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
01/11/2021 | 08:30am EST
share with twitter
share with LinkedIn
share with facebook
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.
In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.
“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity. Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”
Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.
About Silo Pharma
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Company Contact: Investor Relations Contact:
Silo Pharma, Inc.
Eric Weisblum, CEO
Email: eric@silopharma.com Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
Don’t understand why the stock is having a sell the news moment?
$SILO to fly this morning after announcing that it has entered into an agreement that validates its work and adds $1 million to its books. https://cnafinance.com/silo-stock-silo-pharma-enters-licensing-agreement/
SILO~~Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
01/06/2021 | 08:15am EST
share with twitter
share with LinkedIn
share with facebook
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma’s patent applications relates to using a novel peptide with Psilocybin as a therapeutic.
Eric Weisblum, CEO of Silo Pharma, Inc, stated “We are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs that can lead to improved care. This agreement is structured to provide $500,000 in an upfront cash payment as well as equity currently valued at $500,000 from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.”
About Silo Pharma
Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
SILO got my interest from a poster on another board. After a little digging I discovered that this CEO had been involved in reverse splits in the past and tried to cover up their audit trails by renaming the the company (common tactic). Just do some DD on ticker SPEX (3 R/S in less than 2 years). THe company was subsequently renamed to hide the R/S history. This does not look good. Also the BOD pretty much only has this CEO (Eric Weisblum) on it. If you look up his history you will discover that he has made his fortune by being clever with OTC stocks which usually damages the SH.
Why anyone would still pay that dead group to pump anything is beyond me. Their chatroom has 2 real people and 7-8 fake bots sitting there. Main person never traded a day in his life, but I guess if they still have an email list they can get paid to push crap to them.
Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide ("LSD") to Treat Parkinson’s Disease
https://finance.yahoo.com/news/silo-pharma-announces-plans-phase-133000255.html
Wednesdays New Blockbuster Biotech Stock (SILO) Poised to Breakout!
Wall Street Elites and Silicon Valley Are Investing Heavy Into This Space!
Dear Fellow Trader,
What if you could buy shares of Pfizer when it was a tiny, little-known company?
If you bought and held this biotech stock, even if all you bought is a few thousand bucks, you would be a multi-millionaire right now.
I’ve identified the next early-stage biopharmaceutical stock that could potentially ride the next biotech breakout wave.
Immediately turn your attention to Silo Pharma Inc. (SILO)
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to innovatively address underserved conditions including Fibromyalgia, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.
Wall Street & Silicon Valley Leaders Are Rushing
to Support Psychedelic Medicine
As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley.
Peter Thiel, the notable billionaire backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of aforementioned Palantir Technologies, which posted its best week since it went public in September, adding about $17BIL in market value as a broad rally in tech stocks helped fuel gains in the software maker.
Currently, Palantir is one of the tech industry’s most valuable private companies with a whopping valuation of $20BIL. Thiel’s combined investments in Palantir and Compass Pathways highlights the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley.
Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, Thiel may be onto something by investing in the psilocybin sector!
Introducing... SILO!
Now Turn Your Complete Attention to SILO
Wednesday's Focus Stock...
For investors of Silo Pharma, Inc. (SILO), a early-stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, and general supporters of the psilocybin and ‘magic mushroom’ market, the passage of a ballot measure in Oregon just a few weeks ago to allow licensed providers to administer the hallucinogenic substance found in magic mushrooms is a significant development. As some may recall, Oregon was the first state to decriminalize the possession of small amounts of cannabis, and among the first to authorize its use for medical purposes.
Pioneering Oregon then proved a safe and regulated commercial market for cannabis and state after state continues to follow. It is worth noting that Washington D.C. passed a similar measure for mushroom based psychedelics.
And what is also of interest is that as these seminal legislative changes occur, Silo Pharma seeks to develop its own standing in the markets, having recently announced its transition from the OTC Pink Market to the OTCQB® Venture Market.
It’s a significant move through the transparency required of OTCQB companies, being quoted on a more senior quotation medium, and introducing the Company to a possible greater pool of retail investors and institutions.
Psilocybin is in its infancy, and Silo Pharma appears to be in a nascent phase of its business plan despite a partnership with a major university already in place. As these new markets open up in Oregon and D.C., Silo is preparing to meet the moment.
Catalyst #1 Bullish Catalyst – Silo Pharma Announces Blockbuster Patent News of Three U.S. Provisional Patent Applications.
Silo Pharma, Inc. Announces Filing of Three
U.S. Provisional Patent Applications
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced the filing of three distinct U.S. Provisional Patent applications with the U.S. Patent and Trademark Office ("USPTO") pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these provisional patents relates to the continued research and development of the central nervous system-homing peptides covered by the UMD option agreement to deliver certain compounds,” stated Eric Weisblum, Chairman and CEO of Silo Pharma.” We are excited to have taken this important action with respect to our recently announced collaboration with UMD.”
A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes more and more competitive, a provisional patent application successfully establishes an early effective filing date and allows the patent applicant or a licensee to ascribe the phrase "patent pending" to any product development and methodologies associated with the patent’s subject matter.
“These patent applications, together with Silo’s efforts to bring scientific talent, resources, and industry leaders together, allows the Company to continue its development of novel therapeutics in the psychedelic category,” stated Mr. Weisblum.
Catalyst #2 Bullish Catalyst – Another bullish catalyst is SILO Launches Scientific Advisory Board with Appointment of a Physician of John Hopkins University.
“Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”
Catalyst #3 Bullish Catalyst – Another bullish catalyst is Silo Pharma announced
Blockbuster News they're to explore unique peptide delivery of psilocybin utilizing this novel technology represents key differentiator in emerging psilocybin space.
Silo Pharma announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.
This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS).
These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.
“The option agreement gives Silo access to a potential unique and vital approach which significantly differentiates us within the Psilocybin space,” stated Eric Weisblum Chairman and CEO of Silo Pharma. “The ability to deliver psilocybin and other psychedelic compounds directly to targeted areas of the body with this technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases. We believe this novel approach coupled with our planned research of psilocybin as a therapeutic presents an exciting time for the company.”
As you can see, there are multiple bullish catalysts signaling breakout gain potential!
It’s important to remember that historically small-cap biotech companies have been my biggest gainers that are cut from the same cloth as SILO!
I am urging all of our members to add SILO to the top of their watch list right now, and be ready this morning at the opening bell!
Regards,
Your PPF Team
007 pumping this tomorrow got email
New Update #1 New Blockbuster Biotech Stock Silo Pharma (SILO) Set to EXPLODE
As Wall Street & Silicon Valley Invest Heavy Into This Space!
Dear Fellow Trader,
What if you could buy shares of Pfizer when it was a tiny, little-known company?
If you bought and held this biotech stock, even if all you bought is a few thousand bucks, you would be a multi-millionaire right now.
I’ve identified the next early-stage biopharmaceutical stock that could potentially ride the next biotech breakout wave.
Immediately turn your attention to Silo Pharma Inc. (SILO)
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to innovatively address underserved conditions including Fibromyalgia, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.
Wall Street & Silicon Valley Leaders Are Rushing
to Support Psychedelic Medicine
As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley.
Peter Thiel, the notable billionaire backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of aforementioned Palantir Technologies, which posted its best week since it went public in September, adding about $17 billion in market value as a broad rally in tech stocks helped fuel gains in the software maker.
Currently, Palantir is one of the tech industry’s most valuable private companies with a whopping valuation of $20 billion dollars. Thiel’s combined investments in Palantir and Compass Pathways highlights the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley.
Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, "Thiel may be onto something by investing in the psilocybin sector."
Introducing... SILO!
Now Turn Your Complete Attention to SILO
Wednesday's Focus Stock...
For investors of Silo Pharma, Inc. (SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, and general supporters of the psilocybin and ‘magic mushroom’ market, the passage of a ballot measure in Oregon just a few weeks ago to allow licensed providers to administer the hallucinogenic substance found in magic mushrooms is a significant development. As some may recall, Oregon was the first state to decriminalize the possession of small amounts of cannabis, and among the first to authorize its use for medical purposes.
Pioneering Oregon then proved a safe and regulated commercial market for cannabis and state after state continues to follow. It is worth noting that Washington D.C. passed a similar measure for mushroom based psychedelics.
And what is also of interest is that as these seminal legislative changes occur, Silo Pharma seeks to develop its own standing in the markets, having recently announced its transition from the OTC Pink Market to the OTCQB® Venture Market.
It’s a significant move through the transparency required of OTCQB companies, being quoted on a more senior quotation medium, and introducing the Company to a possible greater pool of retail investors and institutions.
Legalized psilocybin is in its infancy, and Silo Pharma appears to be in a nascent phase of its business plan despite a partnership with a major university already in place. As these new markets open up in Oregon and D.C., Silo is preparing to meet the moment.
And now to add more Breakout-Fuel to this bullish pick is their latest Blockbuster Patent News!
Silo Pharma, Inc. Announces Filing of Three
U.S. Provisional Patent Applications
Each Provisional Patent Application Relates to Psilocybin
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced the filing of three distinct U.S. Provisional Patent applications with the U.S. Patent and Trademark Office ("USPTO") pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these provisional patents relates to the continued research and development of the central nervous system-homing peptides covered by the UMD option agreement to deliver certain compounds,” stated Eric Weisblum, Chairman and CEO of Silo Pharma.” We are excited to have taken this important action with respect to our recently announced collaboration with UMD.”
A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes more and more competitive, a provisional patent application successfully establishes an early effective filing date and allows the patent applicant or a licensee to ascribe the phrase "patent pending" to any product development and methodologies associated with the patent’s subject matter.
“These patent applications, together with Silo’s efforts to bring scientific talent, resources, and industry leaders together, allows the Company to continue its development of novel therapeutics in the psychedelic category,” stated Mr. Weisblum.
SILO also has several more bullish catalysts working in its favor:
Another bullish catalyst is SILO recently appointed of Dr. Matthew Johnson of John Hopkins University as a member of the advisory board.
Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior.
Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit of market opportunities for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics.
Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Another bullish catalyst is SILO to Explore Unique Peptide Delivery of Psilocybin Utilizing this Novel Technology Represents Key Differentiator in Emerging Psilocybin Space.
SILO announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.
This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS). These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.
“The option agreement gives Silo access to a potential unique and vital approach which significantly differentiates us within the Psilocybin space,” stated Eric Weisblum Chairman and CEO of Silo Pharma. “The ability to deliver psilocybin and other psychedelic compounds directly to targeted areas of the body with this technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases. We believe this novel approach coupled with our planned research of psilocybin as a therapeutic presents an exciting opportunity for the company.”
As you can see, there are multiple bullish catalysts signaling breakout gain potential!
It’s important to remember that historically, small-cap biotech, biopharmaceutical,
life sciences, nutraceutical and therapeutics companies have been my biggest gainers that are cut from the same cloth as SILO!
I am urging all of our members to add SILO to the top of their watch list right now, and be ready Wednesday morning at the opening bell!
?SamuraiStocks
Trading Research Team
Stock at $0.34. Lots of dumping my friend.
I tried to warn you it was coming back to low $0.20s.
You could have saved a lot of money. For you that might be $200.
Lol.
Dropped big time at end of day.
Selling will continue until low $0.20’s.
See you later.
CVLB much better investment than this crap.
Nasdaq in 2 weeks. Good quarterly results.
SILO is just a POS moving back to $0.20 or lower.
Sorry Pawny.
Waa waa waa.
Huge dump today into that fluff news.
Mobbing back to $0.20 or lower.
Waa waa waa.
Lol.
What makes you think they're going to raise at $0.25? Why wouldn't they raise at $0.50?
Buyer beware. Adam Wasserman Involved. He was fined by SEC and now on probation.
I would run far away from this crap.
Pump to close the financing at $0.25.
When it gets announced this will fall hard.
Likely will drop 50% from current levels.
Shady management.
Bid has dropped to $0.20’s.
Poor Pawny.
He just cannot pick a stock.
Waa
Waa
Waa
Waa
$0.36. Down 7%.
Waa waa waa
Go cry to mommy because your 1000 shares of SILO are dropping.
See you are under $0.25.
How’s MGON?
Waa
Down big today buddy.
SILO likely will announce financing at $0.25.
See you there buddy.
Lol.
Sorry Pawny but this crap stock sucks.
Did you see that huge sell off at EOD?
More to come my friend
Don't let them get your shares. They need to be pumped up in order to attract traders. But they don't want to pay you , so they create a manipulation to throw you off the boat and float far up! A break of $ 0.50 will give a strong acceleration and attract new buyers, and we will see$1+
This will move up. Volume was created , now pumping. They stopped for a couple of days, in order to get rid of weak hands and extra weight in the form of you.
Do they announce that dilutive financing today at $0.25?
How hard does this crap crash?
Even Psychiatrist are against psilocybin for PTSD.
That is very very concerning.
Financings are the killer of OTC stocks.
How low does this POS go?
I am guessing $0.25 but it might even drop lower.
I am placing a stink bid at $0.15.
Time will tell.
What do Psychiatrist say about psilocybin?
This is not good for a one trick pony like SILO.
Buyer beware.
opposition in the pamphlet came from the Oregon Psychiatric Physicians Association and the American Psychiatric Association.
"We believe that science does not yet indicate that psilocybin is a safe medical treatment for mental health conditions," the groups said.
https://kval.com/news/local/measure-109-legalize-psilocybin-for-therapeutic-use-11-04-2020
SILO filed prospectus to dilute 30 million shares.
Doesn’t give a price but likely $0.25.
No need to rush and buy this crap.
Looks who involved in this stock.
Sounds fishy to me.
The Securities and Exchange Commission has charged the U.S.-based former CFO of a public company based in China with improperly commingling corporate and personal funds as part of a practice to transfer funds to the U.S. while avoiding foreign currency controls.
According to the SEC's complaint, over a 20-month period, Adam C. Wasserman used a personal account to transfer over $400,000 in corporate funds from China to the U.S
POS scam SILO down big today.
Pawns lost $200 and crying to his mommy.
See you at $0.25
This POS is moving back to $0.25.
That is a no brainer.
I am planning on buying at $0.25 and selling at $0.30.
Another OTC scam here?
It appears that Wayne Linsley is a board of director. Why is that important?
Well he has been involved with CFO Oncall, Inc.
Why is that important?
Because good old Wasserman is CEO and majority stockholder of CFO Oncall, Inc.
You can never ever trust some of these OTC stinky pinkies.
It is always so important to do careful DD on these plays.
News Out!!!
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has formed a Scientific Advisory Board for evaluating opportunities to advance strategies related to the use of psychedelic and psilocybin drug therapies. The company appointed addiction medicine and drug dependence researcher Dr. Matthew W. Johnson, Ph.D. as a member of the advisory board.
“Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”
Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior. Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit of market opportunities for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics. Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004 and his Bachelor of Science at Eastern Oregon University in 1998.
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
https://www.globenewswire.com/news-release/2020/11/09/2122631/0/en/Silo-Pharma-Inc-Launches-Scientific-Advisory-Board-with-Appointment-of-Dr-Matthew-Johnson-of-John-Hopkins-University.html
$SILO will be back to $.60 in a heartbeat...
Then we test all time highs of $1.50...
$SILO = Low Float & a Great Cutting Edge Alternative to Big Pharma...
Tick-tock...
Psilocybin is a revolutionary therapy that just got green lit by Oregon...
More states/countries to follow...
Under a Harris/Biden admin psilocybin therapy probably gets funding!!!
Any shares below $1.00 & you've bought in on the ground floor!!
Just my opinion,
Do you own D.D.
Psilocybin therapy 4x more effective than anti-depressants...
https://newatlas.com/health-wellbeing/psilocybin-therapy-major-depression-trial-results-johns-hopkins/
$SILO only the beginning...
$SILO is one of those stocks you BUY & NEVER SELL...
$SILO gonna be worth $$$s under a Harris/Biden admin...
Just my opinion,
Do you own D.D.
SILO on the move higher. Not much stock out there, so we could see $1.00 quick with this kind of volume.
Oregon first state to LEGALIZE psilocybin therapy...
Voters approved Measure #109 by a slim 49% to 40% margin...
Oregon will be the first state to legalize psychedelic therapy!!
This is a game-changer for those suffering from PTSD and other horrible afflictions...
https://www.wweek.com/news/state/2020/11/03/oregon-votes-to-legalize-psilocybin-therapy-and-decriminalize-small-quantities-of-hard-drugs/
Hope everybody got some cheapies...
$SILO gonna be worth Dollars $$$
IMO
Do you own D.D.
If/When Oregon passes IP34 tonight legalizing psilocybin therapy $SILO will take off like a rocket ship!!
In the Harris/Biden admin psychedelic treatment will be greenlit & $SILO will be one of the industry leaders.
IMO
Do your own D.D.
https://www.motherjones.com/politics/2020/11/oregon-ballot-magic-mushrooms-psychedelic-psilocybin-therapy/
Uppercut Brands Inc., UCUT, changed to Silo Pharma Inc., SILO:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Point Capital Inc., PTCI, changed to Uppercut Brands Inc., UCUT:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Adam Wasserman spanked by the SEC today. $20,000.00 fine and 5 year ban. Hes also involved in WLYW.
Gold Swap Inc., GDSW, changed to Point Capital, Inc., PTCI:
http://www.otcbb.com/asp/dailylist_detail.asp?d=01/24/2013&mkt_ctg=OTCBB
Gold Swap Inc. a development-stage company, formed to facilitate the broad-scale recycling of jewelry, and other items containing precious metals in the United States and internationally. The Company is focused to utilize consumer oriented advertising efforts to solicit individuals interested in liquidating unwanted jewelry and other items containing precious metals. Through a global platform, the Company will facilitate an end-to-end consumer solution, from acquisition of the used jewelry through liquidation. Its focus will be on providing a service that will enable the public to discretely sell their precious metals from their homes or offices. As of December, 31, 2010, the Company had not generated any revenues.
Its a watcher.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
130
|
Created
|
01/17/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |